Peripheral/Endo

6-Month Data from the Surmodics SWING First-in-Human Study to be Presented at AMP Europe

35-subject trial evaluating safety, performance of Surmodics’ Sundance™ Sirolimus Drug-Coated Balloon EDEN PRAIRIE, Minn.–(BUSINESS WIRE)–Surmodics, Inc. (NASDAQ:SRDX), a leading provider of medical device and in vitro diagnostic technologies to the health care industry, announced today that Professor Ramon Varcoe will present 6-month data from the SWING Trial, a first-in-human study of […]

Microbot Medical Strengthens LIBERTY® Robotic System Portfolio with Acquisition of Novel FDA-Cleared Devices

Integration with the LIBERTY® Robotic System & One & Done™ Technology May Enable Future Acceleration of Robotic Adoption; Represents an Additional Growth Opportunity by Accessing the $500 Million Chronic Total Occlusion (CTO) Market1 through the Expansion of Robotic Ecosystem for Endovascular Procedures HINGHAM, Mass., Oct. 07, 2022 (GLOBE NEWSWIRE) — Microbot […]

VentureMed Announces First Patient Treated With The FLEX Vessel Prep™ System AV Focused 75cm Product

MINNEAPOLIS, Oct. 5, 2022 /PRNewswire/ — VentureMed Group, Inc., a privately held medical device innovator in access management for arteriovenous (AV) fistulas and grafts and vessel preparation for interventional treatment of peripheral arterial disease (PAD) announced today that Dr. Ari Kramer, Assistant Professor, Department of Surgery and Director, Vascular Access Program, Spartanburg Regional Healthcare […]

REVA MEDICAL ANNOUNCES INITIATION OF ENROLLMENT IN THE MOTIV IDE CLINCIAL TRIAL

SAN DIEGO, Sept. 27, 2022 /PRNewswire/ — REVA Medical, LLC, a leader in bioresorbable polymer technologies for vascular applications, today announced that enrollment in the MOTIV pivotal trial has been initiated at clinical centers in both the U.S. and Europe. The study will evaluate the use of the MOTIV® Sirolimus-Eluting Bioresorbable Vascular Scaffold for […]

Penumbra and Asahi Intecc Partner With Goal of Introducing Indigo™ System Including Lightning™ Intelligent Aspiration to Japan

Companies aim to introduce Penumbra’s most advanced peripheral mechanical thrombectomy technology to Japan upon regulatory approval Lightning technology is designed for single session blood clot removal in peripheral arterial and venous systems, including for diseases such as acute limb ischemia, vein thrombosis and pulmonary embolism First and only computer-aided mechanical […]

Efemoral Medical Awarded Phase II SBIR Grant from NIH to Advance Treatment for Peripheral Artery Disease

Grant Proceeds Will Support Pre-Clinical Studies LOS ALTOS, Calif., Sept. 22, 2022 /PRNewswire/ — Efemoral Medical, developer of advanced interventional bioresorbable therapies, announced today that it has been awarded a Phase II Small Business Innovation Research (SBIR) grant by the National Institutes of Health. SBIR grants are intended to stimulate technological innovation and […]

Inari Medical Announces Results from the Fully Enrolled 800-patient US Cohort of the FlowTriever FLASH Registry

IRVINE, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous and other diseases, announced positive outcomes of the fully enrolled 800-patient FLASH registry in pulmonary embolism (“PE”). […]

AVS Announces Multi-Site Enrollment of First Patients in POWER PAD I Clinical Trial and Appointment of William H. Kucheman to Board of Directors

Pulsatile Intravascular Lithotripsy shows promise as new treatment therapy for severely calcified vessels ANN ARBOR, Mich.–(BUSINESS WIRE)–AVS, an early-stage medical device company focused on safely and effectively treating severely calcified arterial disease with its PIVL™ therapy, today announced enrollment, successful treatment, and positive 30-day follow up data of the first […]

THE SAGE GROUP Comments on National Peripheral Artery Disease (PAD) Awareness Month

BEAUFORT, S.C.–(BUSINESS WIRE)–According to THE SAGE GROUP, 21 million Americans suffer from PAD representing an economic burden of $283-$539 billion. “Twenty years ago we wrote that PAD was underestimated, underdiagnosed and undertreated,” stated Mary L. Yost, President. “Unfortunately, this is still true.” Reflecting on the current state of PAD and […]

ABK Biomedical announces FDA 510(k) clearance of Easi-Vue™ embolic microspheres for the embolization of arteriovenous malformations and hypervascular tumors

HALIFAX, Nova Scotia, Sept 12, 2022 – ABK Biomedical, Inc., an innovative medical device company dedicated to the research, development, and commercialization of advanced imageable embolic therapies, announces FDA 510(k) clearance of Easi-Vue embolic microspheres for the treatment of patients suffering from arteriovenous malformations and hypervascular tumors. Arteriovenous malformations (AVMs) […]